US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

VictoryShares US Discovery Enhanced Volatility Wtd ETF

50.92

+0.10190.20%

Post-market: 50.89-0.0309-0.06%16:05 EDT

Volume:2.74K

Turnover:139.47K

Market Cap:25.46M

PE:- -

High:50.92

Open:50.84

Low:50.84

Close:50.82

Loading ...

Overview Company News Filings

Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th

Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025

Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025

Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program

Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis

Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing

Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa

Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development

Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS

JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage Disorders

Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™

JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones

Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis

Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease

Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSF/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","market":"US","secType":"STK","nameCN":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","latestPrice":50.9209,"timestamp":1744920000000,"preClose":50.819,"halted":0,"volume":2742,"hourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"delay":0,"floatShares":500000,"shares":500000,"eps":0,"marketStatus":"Market Closed","change":0.1019,"latestTime":"04-17 16:00:00 EDT","open":50.84,"high":50.9209,"low":50.84,"amount":139469.3583,"amplitude":0.001592,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745222400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":50.819,"sharesOutstanding":500000,"nav":50.919731,"aum":25459850,"bidAskSpread":0.001349,"preHourTrading":{"tag":"盘前","latestPrice":50.819,"preClose":50.819,"latestTime":"08:02 EDT","volume":8,"amount":406.552,"timestamp":1744891358272},"postHourTrading":{"tag":"盘后","latestPrice":50.89,"preClose":50.9209,"latestTime":"16:05 EDT","volume":2,"amount":101.8418,"timestamp":1744920313821},"volumeRatio":0.3635254778799937},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSF\",,,,,undefined,":{"symbol":"CSF","floatShares":500000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.3635254778799937,"shares":500000,"dividePrice":0.78061,"high":50.9209,"amplitude":0.001592,"preClose":50.819,"low":50.84,"week52Low":47.7503,"pbRate":"--","week52High":60.63,"institutionHeld":0,"latestPrice":50.9209,"eps":0,"divideRate":0.01533,"volume":2742,"delay":0,"ttmEps":0,"open":50.84,"prevYearClose":54.8761,"prevWeekClose":50.7,"prevMonthClose":51.5505,"prevQuarterClose":51.5505,"fiveDayClose":50.55,"twentyDayClose":52.06,"sixtyDayClose":56.7724},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSF\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2513740158","title":"Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th","url":"https://stock-news.laohu8.com/highlight/detail?id=2513740158","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2513740158?lang=en_us&edition=fundamental","pubTime":"2025-02-24 20:00","pubTimestamp":1740398400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Feb. 24, 2025 /PRNewswire/ --Nektar Therapeutics  today announced that it will host a virtual investor and analyst event with Type 1 Diabetes  Experts on Monday, February 24, 2025 at 3:00 p.m. EST / 12:00 p.m. PST.Nektar's Chief Research & Development Officer, Jonathan Zalevsky, Ph.D., will be hosting the webcasted event. He will be joined by leading Diabetesexperts, including:. Dr. Kevin Herold, TrialNet Chair and C.N.H. Long Professor of Immunobiology and Medicine at Yale University at Yale School of Medicine;Dr. Megan Levings, Professor, Department of Surgery and School of Biomedical Engineering at The University Of British Columbia; and,Dr. Daniel Moore, Associate Professor of Pediatrics and Pathology, Microbiology & Immunology at Vanderbilt University Medical Center.The U.S. Food and Drug Administration  has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-host-virtual-investor-120000319.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-host-virtual-investor-120000319.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4218","BK4588","BK4181","CSF","HST","BK4007","NKTR","BK4585"],"gpt_icon":0},{"id":"2512264446","title":"Seer to Feature Proteomic Advancements in Cancer and RNA Therapy Research among other Findings at US HUPO 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512264446","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512264446?lang=en_us&edition=fundamental","pubTime":"2025-02-20 20:00","pubTimestamp":1740052800,"startTime":"0","endTime":"0","summary":"Seminar from Dr. Jinjun Shi from Brigham and Women's Hospital and Harvard Medical School to highlight study of proteomic perturbations resulting from a novel approach to cancer therapy revealed using Seer’s Proteograph Product Suite. Additional presentations from Seer and collaborators will highlight the Proteograph Product Suite’s role in deep proteomic studies to understand tissue biology, uncover biomarkers for cardiometabolic dysfunction, enable advancements in mass spectrometry proteomics throughput, and leverage model organisms to advance human health.In this sponsored seminar, Dr. Shi will present novel findings from a first-of-i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/seer-feature-proteomic-advancements-cancer-120000159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RNA","BK4588","CSF","BK4121","SEER","BK4505","BK4585"],"gpt_icon":0},{"id":"2512915233","title":"Ultragenyx Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512915233","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512915233?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"NOVATO, Calif., Feb. 18, 2025  -- Ultragenyx Pharmaceutical Inc.  today announced the U.S. Food and Drug Administration  has accepted for review the Biologics License Application  seeking accelerated approval for UX111  AAV gene therapy as a treatment for patients with Sanfilippo syndrome type A . The FDA granted the BLA Priority Review with a Prescription Drug User Fee Act  action date of August 18, 2025. The FDA also informed the company that they are not currently planning to hold an advisory committee meeting to discuss this application.“Acceptance of the UX111 BLA brings us closer to being able to provide a first-ever treatment for Sanfilippo syndrome type A and, if our application is successful, we’re prepared to launch this therapy for patients and their families,” said Emil D. Kakkis, M.D., Ph.D., chief executive officer and president of Ultragenyx. “By reaching alignment with the Agency on a path forward for accelerated approval in neuronopathic MPS diseases, our UX111 program","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ultragenyx-announces-fda-acceptance-priority-130000271.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","RARE","CSF"],"gpt_icon":0},{"id":"2512151777","title":"Fonar Announces Six Month and 2nd Quarter Financial Results for Fiscal 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2512151777","media":"Newsfile","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512151777?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:37","pubTimestamp":1739882220,"startTime":"0","endTime":"0","summary":"MRI scan volume at HMCA managed sites increased 7% to 79,207 scans during the six-month period ended December 31, 2024, versus 73,776 scans for the six-month period ended December 31, 2023. MRI scan volume at HMCA owned sites decreased 4% to 26,961 scans during the six-month period ended December 31, 2024, versus 28,214 scans for the six-month period ended December 31, 2023.Cash and Cash Equivalents and Short-term Iinvestments decreased 5% to $53.7 million at December 31, 2024, versus the fiscal year ended June 30, 2024.Total Revenues-Net for the six-month period ended December 31, 2024, decreased by 3% to $49.9 million, and for the quarter ended December 31, 2024, decreased by 2% to $25.0 million, versus the corresponding periods one year earlier.Income from Operations for the six-month period ended December 31, 2024, decreased 38% to $7.2 million, and for the quarter ended December 31, 2024, decreased 48% to $2.6 million, versus the corresponding periods one year earlier.Diluted Net ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/fonar-announces-six-month-2nd-123700829.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fonar-announces-six-month-2nd-123700829.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4082","MIT","CSF","FONR"],"gpt_icon":0},{"id":"2512915111","title":"Press Release: Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program","url":"https://stock-news.laohu8.com/highlight/detail?id=2512915111","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512915111?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:31","pubTimestamp":1739881860,"startTime":"0","endTime":"0","summary":"$3.7 Million Private Placement Financing from Existing Investors. $2.0 Million Funding Advance from the Cancer Prevention and Research Institute of Texas . \"We are grateful for the enthusiasm and ongoing support from both existing investors and key funding agencies, including CPRIT, the National Institutes of Health, and the U.S. Department of Defense,\" said Marc H. Hedrick, M.D., Plus Therapeutics' President and Chief Executive Officer. \"This capital, along with expected grant allocations later in 2025, is expected to fully support the completion of two planned LM trials, strategically positioning the company for a pivotal trial in 2026.\". The gross proceeds to the Company from the private placement were approximately $3.7 million, before deducting offering expenses payable by the Company. The Company currently intends to use the net proceeds from the private placement for general corpo","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4585","PSTV","NGS","CNS","BK4099","CSF","BK4604","BK4555","NCI","TM","BK4139","BK4179","BK4202","LENZ","BK4135","BK4588"],"gpt_icon":0},{"id":"2510859391","title":"Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2510859391","media":"PR Newswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510859391?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:00","pubTimestamp":1739188800,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Feb. 10, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced that the U.S. Food and Drug Administration  has granted Fast Track designation for rezpegaldesleukin for the treatment of adult and pediatric patients 12 years of age and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Rezpegaldesleukin is an investigational biologic therapy that targets the interleukin-2 receptor complex in the body in order to stimulate proliferation of inhibitory immune cells known as regulatory T cells .In patients with moderate-to-severe atopic dermatitis, rezpegaldesleukin has been shown to rapidly improve measurable exploratory disease outcomes during a 12-week induction treatment phase and for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.1 Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegal","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-receives-fast-track-120000179.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-receives-fast-track-120000179.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00BFXG0V08.USD","IE00BYQQ9H92.USD","IE00B5TLWC47.USD","BK4104","CSF","BK4585","BSA","FAST","BK4007","NKTR","BK4588","BK4567","EASI"],"gpt_icon":0},{"id":"2509207040","title":"Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing","url":"https://stock-news.laohu8.com/highlight/detail?id=2509207040","media":"Benzinga","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509207040?lang=en_us&edition=fundamental","pubTime":"2025-02-07 02:30","pubTimestamp":1738866612,"startTime":"0","endTime":"0","summary":"On Thursday, Coya Therapeutics, Inc. announced blood biomarker data from an investigator-initiated, 21-week, double-blind, placebo-controlled, exploratory Phase 2 study of LD IL-2 in patients with Alzheimer’s disease .Statistically significant reduced levels of proinflammatory markers were observed in patients receiving a five-day treatment of subcutaneous LD IL-2 on a monthly cycle in comparison to a biweekly 5-day administration or placebo.Also Read: EXCLUSIVE: Coya Therapeutics Expands Its Pipeline With Combo Therapy For Inflammatory Diseases. Lower blood levels of the proinflammatory chemokine  ligand 2   and proinflammatory cytokine IL-15  were statistically significant. A statistically significant increase in the anti-inflammatory cytokine IL-4  in patients receiving monthly cycles of LD IL-2 was observed compared to patients receiving a placebo.In addition, patients receiving LD IL-2 cycles at the higher biweekly frequency showed a smaller impact on these factors than monthly LD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-alzheimers-candidate-shows-183012854.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["COYA","CSF","LENZ","BK4139"],"gpt_icon":0},{"id":"2509206203","title":"Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa","url":"https://stock-news.laohu8.com/highlight/detail?id=2509206203","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509206203?lang=en_us&edition=fundamental","pubTime":"2025-02-07 00:42","pubTimestamp":1738860120,"startTime":"0","endTime":"0","summary":"Long-term data demonstrate that robust reductions and normalization in key biomarkers from baseline were maintained over time with continued improvement in hearing, cognition and adaptive behaviorLong","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/06/3022238/0/en/Denali-Therapeutics-Announces-Primary-Analysis-and-Long-Term-Follow-Up-of-Phase-1-2-Study-in-Hunter-Syndrome-MPS-II-with-Tividenofusp-Alfa.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TV","BK4535","CSF","BK4548","ETV","LENZ","DNLI","BK4139","BK4100"],"gpt_icon":0},{"id":"2509755202","title":"Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer’s Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2509755202","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509755202?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:00","pubTimestamp":1738846800,"startTime":"0","endTime":"0","summary":"Investigator-initiated data from Houston Methodist Hospital showed LD IL-2 reduced proinflammatory factors, both systemically and within the central nervous system, while demonstrating statistically significant improvement in beta amyloid 42 clearance with stabilization of cognitive decline over a five-month treatment period. Comprehensive data set will be presented and released throughout 2025 and in a peer reviewed publication. The statistically significant improvement in serum inflammatory markers corresponded with previously-reported findings from AD patients receiving monthly LD IL-2 compared to patients receiving biweekly LD IL-2 or placebo. Monthly LD IL-2 showed an increase in Aβ42 levels in cerebrospinal fluid , suggesting increased clearance of amyloid-β, stable levels of neurofilament light chain  in CSF, and statistically significant Treg expansion, all demonstrating targeted biological activity. In addition, patients receiving monthly LD IL-2 showed a 4.93-point improvemen","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/coya-therapeutics-reports-statistically-significant-130000484.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSF","BK4139","BK4023","LENZ","LU1169589451.USD","COYA","LU1169590202.USD","PD"],"gpt_icon":0},{"id":"2509283185","title":"Ultragenyx Announces New Data Demonstrating that Treatment with UX111 AAV Gene Therapy Significantly Improved Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome Type A (MPS IIIA) Correlated with Sustained Reductions in CSF-HS","url":"https://stock-news.laohu8.com/highlight/detail?id=2509283185","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509283185?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"Modified intent-to-treat group demonstrated +22.7 point  treatment effect in the mean Bayley-III cognitive raw score compared to natural history data . Older children with more advanced disease demonstrated retention of clinically meaningful functional abilities, including communication, ambulation and self-feeding. The latest data from the pivotal Transpher A and long-term follow-up studies will be presented at WORLDSymposium 2025. Cognitive function, expressive and receptive communication and fine and gross motor skills were measured using Bayley-III and compared to natural history data from untreated patients with reported rapid progressor phenotypes.iiMean observed raw scores on the Bayley-III domains improved compared to natural history. The model-based mean Bayley-III cognitive raw score from ages 24 to 60 months in the mITT group improved by +16 points compared to natural history patients who declined by -6.8 points, demonstrating a +22.7 point  treatment effect.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ultragenyx-announces-data-demonstrating-treatment-130000623.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RARE","CSF"],"gpt_icon":0},{"id":"2509740000","title":"JCR Pharmaceuticals’ Research Presentations at WORLDSymposium™ 2025 Showcase Research from Its Investigational Treatments for Lysosomal Storage Disorders","url":"https://stock-news.laohu8.com/highlight/detail?id=2509740000","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509740000?lang=en_us&edition=fundamental","pubTime":"2025-02-05 20:30","pubTimestamp":1738758600,"startTime":"0","endTime":"0","summary":"- Presentations Highlight Potential Benefits of Therapies Incorporating J-Brain Cargo, JCR’s Proprietary, Blood-Brain Barrier-Penetrating Technology -. HYOGO, Japan, February 05, 2025----JCR Pharmaceuticals Co., Ltd.  today announced the presentation of two datasets demonstrating the potential benefits of its investigational therapies for lysosomal storage disorders  at the 21st Annual WORLDSymposiumTM 2025. JCR is presenting new data from a pair of its programs that apply its J-Brain Cargo platform, a proprietary technology developed by JCR, to deliver medicines across the blood-brain barrier  through poster presentations this week.The first presentation highlights non-clinical data from the JR-479 clinical development program. JR-479 is an investigational BBB-penetrating β-Hexosaminidase A  enzyme replacement therapy  that JCR is developing for the treatment of people with GM2 gangliosidoses.This late-breaking poster presentation provides non-clinical data from the JR-479 clinical de","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jcr-pharmaceuticals-research-presentations-worldsymposium-123000703.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4135","CNS","BK4007","JCRRF","CSF"],"gpt_icon":0},{"id":"2507407046","title":"Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™","url":"https://stock-news.laohu8.com/highlight/detail?id=2507407046","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507407046?lang=en_us&edition=fundamental","pubTime":"2025-01-30 21:00","pubTimestamp":1738242000,"startTime":"0","endTime":"0","summary":"The presentation schedule at WORLDSymposium 2025 is as follows:. Title: Age-Dependent Reference Intervals for Cerebrospinal Fluid  and Urine Heparan Sulfate  and Dermatan Sulfate  and CSF Gangliosides – Poster #132Session: Clinical Applications – Poster Session IIIDate: Thursday, February 6, 2025Session Time: 3:30 – 5:30 PM Pacific Time. Denali is also sponsoring the following satellite symposium event at WORLDSymposium 2025:. Title: Voices in Unison – Insights into the Unmet Needs in MPS II from Patient Community and Physician Perspectives Date: Wednesday, February 5, 2025Time: 6:45 – 7:45 AM Pacific Time. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements by Denali Therapeutics Inc.  regarding Denali’s planned presentations and events at the ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/denali-therapeutics-announces-upcoming-presentations-130000491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["TV","DNLI","CSF","BK4139","BK4535","BK4100","LENZ","BK4548"],"gpt_icon":0},{"id":"2506105565","title":"JCR Pharmaceuticals to Present at the 21st Annual WORLDSymposium™ 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2506105565","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2506105565?lang=en_us&edition=fundamental","pubTime":"2025-01-28 23:32","pubTimestamp":1738078320,"startTime":"0","endTime":"0","summary":"- Data to be presented in two poster presentations -. HYOGO, Japan, January 28, 2025----JCR Pharmaceuticals Co., Ltd.  announced today that it will present at the 21st Annual WORLDSymposium 2025, held February 3-7, 2025, in San Diego, Calif. The poster presentations will demonstrate the potential benefits of the investigational therapies in JCR’s development pipeline and of J-Brain Cargo, JCR’s proprietary technology that delivers medicine across the blood-brain barrier  for the treatment of lysosomal storage disorders and neurodegenerative disorders.Presentation Title: Treatment with a transferrin receptor-targeted β-hexosaminidase A prolongs life span of GM2 gangliosidosis miceDate/Time: February 4, 2025, 15:30-17:30 PSTPresenter: Kazuki Miyauchi, Scientist Poster Number: LB-33. WORLDSymposium attendees who would like to receive more information about JCR Pharmaceuticals can visit JCR’s on-site conference booth .About Pabinafusp AlfaPabinafusp alfa is a recombinant fusion protein of ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/jcr-pharmaceuticals-present-21st-annual-153200155.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSF","CNS","BK4135","JCRRF","BK4007"],"gpt_icon":0},{"id":"2505045131","title":"Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3","url":"https://stock-news.laohu8.com/highlight/detail?id=2505045131","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505045131?lang=en_us&edition=fundamental","pubTime":"2025-01-24 00:33","pubTimestamp":1737649998,"startTime":"0","endTime":"0","summary":"On Thursday, Vigil Neuroscience Inc.  released data from its completed Phase 1 trial evaluating VG-3927 as a potential treatment for Alzheimer’s disease.Key takeaways from the Phase 1 clinical trial ofVG-3927 include:. Demonstrated a favorable safety and tolerability profile across all cohorts, including the elderly cohort.All related adverse events were mild or moderate in severity and self-resolving without drug discontinuations. No serious AEs were reported.Highly brain penetrant with a favorable and predictable PK profile that supports once-daily dosing.Achieved robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid , demonstrating a strong PK/PD relationship, sustained target engagement, and TREM2 agonist activity.PK and sTREM2 reduction observed in the Alzheimer’s cohort was consistent with healthy volunteers and similar across evaluated TREM2 and ApoE genetic variants supporting development in Alzheimer’s disease across genotypes.An","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neurosciences-alzheimers-candidate-shows-163318630.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1720051108.HKD","BK4504","SSI","LU0158827781.USD","BK4588","IE00BKVL7J92.USD","LU0225283273.USD","BK4534","LU1668664300.SGD","LU0106831901.USD","LU2357305700.SGD","BK4139","LU1989772840.SGD","LU0314104364.USD","LU1548497426.USD","BK4581","LU1363072403.SGD","LU2028103732.USD","LU0158827948.USD","LU1732799900.SGD","IE00BZ1G4Q59.USD","LU0971096721.USD","LU2347655156.SGD","BK4585","LU1720051017.SGD","LU2271345857.HKD","BK4127","BK4516","LU0795875086.SGD","LU0795875169.SGD","LU0098860793.USD","LU2023251221.USD","LU1162221912.USD","LU2133065610.SGD","LU1074936037.SGD","CSF","LU0320765646.SGD","LU2089283258.USD","LU0267386448.USD","VIGL","LU2111349929.HKD","LU1732800096.USD","LU1989772923.USD","LU2089284900.SGD","LU0912757837.SGD","LU0006306889.USD","LU0106261372.USD"],"gpt_icon":0},{"id":"2505094867","title":"Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for the Potential Treatment of Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2505094867","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505094867?lang=en_us&edition=fundamental","pubTime":"2025-01-23 20:00","pubTimestamp":1737633600,"startTime":"0","endTime":"0","summary":"- Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease  -. - Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement –。WATERTOWN, Mass., Jan. 23, 2025  -- Vigil Neuroscience, Inc. , a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD. Collectively, the safety, tolerability, pharmacokinetic , and pharmacodynamic  profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral therapy for AD.Achieved robust and dose-dependent reduction of sTREM2 of up to approximately 50% in the cerebral spinal fluid  demonstrating a strong PK/PD relationship, sustained target engagement ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/vigil-neuroscience-reports-positive-data-120000246.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PK","BK4181","BK4139","BK4081","VIGL","ARIA","BK4218","LU1169589451.USD","LU1169590202.USD","BK4023","CSF","VG","PAM","BK4563","PD"],"gpt_icon":0},{"id":"2503852085","title":"Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2503852085","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503852085?lang=en_us&edition=fundamental","pubTime":"2025-01-14 21:00","pubTimestamp":1736859600,"startTime":"0","endTime":"0","summary":"First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with re","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/14/3009229/0/en/Ventyx-Biosciences-Highlights-2025-Pipeline-Strategy-and-Provides-Clinical-Updates-on-its-NLRP3-Inhibitor-Portfolio.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBD","VTYX","BK4007","CSF"],"gpt_icon":0},{"id":"2503607583","title":"Ultragenyx Reports Preliminary 2024 Revenue, Financial Guidance for 2025, Pipeline Updates, and 2025 Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2503607583","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503607583?lang=en_us&edition=fundamental","pubTime":"2025-01-13 00:00","pubTimestamp":1736697600,"startTime":"0","endTime":"0","summary":"Preliminary 2024 total revenue of $555 million to $560 million, exceeding top end of guidance,including Crysvita revenue of $405 million to $410 million, and Dojolvi revenue of $87 million to $89 mill","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/01/12/3008053/20739/en/Ultragenyx-Reports-Preliminary-2024-Revenue-Financial-Guidance-for-2025-Pipeline-Updates-and-2025-Milestones.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4126","BK4139","OI","RARE","CSF"],"gpt_icon":0},{"id":"2502857999","title":"Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis","url":"https://stock-news.laohu8.com/highlight/detail?id=2502857999","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502857999?lang=en_us&edition=fundamental","pubTime":"2025-01-10 20:00","pubTimestamp":1736510400,"startTime":"0","endTime":"0","summary":"SAN FRANCISCO, Jan. 10, 2025 /PRNewswire/ -- Nektar Therapeutics  today announced the company has completed target enrollment in its REZOLVE-AD Phase 2b study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis.Rezpegaldesleukin is a first-in-class interleukin-2 receptor  agonist that proliferates and activates regulatory T cells  with promising dose-dependent clinical activity in multiple skin disease settings. Results from multiple clinical trials showed that rezpegaldesleukin safely and dose-dependently increased Tregs and rapidly improved measurable exploratory disease outcomes in patients with moderate-to-severe atopic dermatitis that were largely durable for at least 36 weeks after ceasing treatment, demonstrating proof-of-concept in this indication.1 Proof-of-concept efficacy and safety data from a Phase 1b study of rezpegaldesleukin in atopic dermatitis patients were presented at the 2023 EADV Congress in October 2023 .This trial was initiated in October ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000533.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/nektar-therapeutics-announces-completion-target-120000533.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BSA","CSF","BK4007","NKTR","EASI"],"gpt_icon":0},{"id":"2501737117","title":"Johnson & Johnson's Posdinemab and Tau Active Immunotherapy Receive U.S. FDA Fast Track Designations for the Treatment of Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2501737117","media":"PR Newswire","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2501737117?lang=en_us&edition=fundamental","pubTime":"2025-01-08 21:00","pubTimestamp":1736341200,"startTime":"0","endTime":"0","summary":"Building on decades of the Company's Alzheimer's research, two differentiated investigational therapies aim to slow pathological tau in distinct populations. TITUSVILLE, N.J., Jan. 8, 2025 /PRNewswire/ -- Johnson & Johnson  announced today that the U.S. Food and Drug Administration  has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody  being investigated to treat patients with early Alzheimer's disease  in the Phase 2b \"AuTonomy\" study.The internally discovered mAb has shown the potential in targeting disease-associated phosphorylated tau in cerebrospinal fluid  from treated AD patients, and in blocking the development and spread of tau aggregates in non-clinical models of disease.ABOUT ALZHEIMER'S DISEASE & DEMENTIA Alzheimer's disease , the most common form of dementia worldwide, is a fatal neurodegenerative disorder characterized by progressive memory loss and a decline in other cognitive abilities severe enough to significantly interfe","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/johnson-johnsons-posdinemab-tau-active-130000739.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/johnson-johnsons-posdinemab-tau-active-130000739.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B1BXHZ80.USD","BK4568","LU1221951129.SGD","SG9999002224.SGD","BK4504","IE0009355771.USD","IE00BGHQF631.EUR","LU1059921491.USD","IE00BVYPNW00.USD","LU0792757196.USD","FAST","BK4534","IE00B19Z3581.USD","BK4007","LU0345769631.USD","IE00BDGV0183.EUR","LU2089984988.USD","LU0234572021.USD","CSF","LU1221951046.USD","BK4533","LU0345770993.USD","IE00B42XCP33.USD","LU1585245621.USD","LU0345770308.USD","LU1894683348.USD","LU1718418525.SGD","LU1196500208.SGD","LU1244550494.USD","JNJ","LU1162221912.USD","LU1894683264.USD","LU1057294990.SGD","LU2133065610.SGD","IE000M9KFDE8.USD","IE00B3PB1722.GBP","BK4550","LU0114720955.EUR","LU0289739699.SGD","LU0466842654.USD","BK4581","LU1732799900.SGD","BK4592","LU0203345920.USD","LU1280957306.USD","IE0002141913.USD","IE00B4R5TH58.HKD","LU1244550221.USD","LU0234570918.USD","LU0889566641.SGD"],"gpt_icon":0},{"id":"2492312729","title":"Alumis Announces Positive Phase 1 Data for CNS Penetrant TYK2 Inhibitor, A-005","url":"https://stock-news.laohu8.com/highlight/detail?id=2492312729","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492312729?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:00","pubTimestamp":1734613200,"startTime":"0","endTime":"0","summary":"– A-005 was well tolerated and demonstrated ability to cross blood-brain barrier – – Maximal TYK2 inhibition achieved with favorable pharmacokinetic profile in CNS and periphery – – Data support advan","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999795/0/en/Alumis-Announces-Positive-Phase-1-Data-for-CNS-Penetrant-TYK2-Inhibitor-A-005.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","LU0106261372.USD","BK4127","LU1989772840.SGD","LU1732800096.USD","ALMS","LU2089284900.SGD","LU0158827948.USD","LU1363072403.SGD","BK4007","LU2357305700.SGD","LU0314104364.USD","BK4504","LU2271345857.HKD","LU2111349929.HKD","BK4218","BK4581","BK4588","LU1169589451.USD","LU2023251221.USD","LU2028103732.USD","LU0971096721.USD","LU0795875169.SGD","BK4516","BK4585","LU1074936037.SGD","LU0225283273.USD","LU1162221912.USD","CNS","LU0795875086.SGD","LU0098860793.USD","BK4023","PK","LU0158827781.USD","LU0267386448.USD","BK4181","IE00BZ1G4Q59.USD","LU0320765646.SGD","IE00BKVL7J92.USD","PD","LU2089283258.USD","LU0106831901.USD","LU1989772923.USD","LU0912757837.SGD","LU1732799900.SGD","LU1169590202.USD","LU1668664300.SGD","LU1548497426.USD","LU1720051108.HKD","CSF"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":68,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSF\",params:#limit:5,,,undefined,":[{"date":"2025-04-10","symbol":"CSF","amount":0.053873,"announcedDate":"2025-04-09","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-10","defaultRemindTime":1744291800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-11","payableDate":"2025-04-10","currency":"USD","dateTimestamp":1744257600000,"payDate":"2025-04-11"},{"date":"2025-03-10","symbol":"CSF","amount":0.09736,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-10","defaultRemindTime":1741613400000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-11","payableDate":"2025-03-10","currency":"USD","dateTimestamp":1741579200000,"payDate":"2025-03-11"},{"date":"2024-12-12","symbol":"CSF","amount":0.194215,"announcedDate":"2024-12-11","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-12","defaultRemindTime":1734013800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-13","payableDate":"2024-12-12","currency":"USD","dateTimestamp":1733979600000,"payDate":"2024-12-13"},{"date":"2024-11-07","symbol":"CSF","amount":0.016451,"announcedDate":"2024-11-06","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-07","defaultRemindTime":1730989800000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-08","payableDate":"2024-11-07","currency":"USD","dateTimestamp":1730955600000,"payDate":"2024-11-08"},{"date":"2024-10-08","symbol":"CSF","amount":0.052247,"announcedDate":"2024-10-07","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-10-08","defaultRemindTime":1728394200000,"name":"VictoryShares US Discovery Enhanced Volatility Wtd ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-10-09","payableDate":"2024-10-08","currency":"USD","dateTimestamp":1728360000000,"payDate":"2024-10-09"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSF\",market:\"US\",,,undefined,":[{"executeDate":"2015-06-16","recordDate":"2015-06-18","paymentDate":"2015-06-19","value":0.0849404,"currency":"USD"},{"executeDate":"2015-09-22","recordDate":"2015-09-24","paymentDate":"2015-09-25","value":0.0863264,"currency":"USD"},{"executeDate":"2015-12-28","recordDate":"2015-12-30","paymentDate":"2015-12-31","value":0.1258576,"currency":"USD"},{"executeDate":"2016-03-08","recordDate":"2016-03-10","paymentDate":"2016-03-11","value":0.0228347,"currency":"USD"},{"executeDate":"2016-06-14","recordDate":"2016-06-16","paymentDate":"2016-06-17","value":0.0798989,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSF\",market:\"US\",delay:false,,,undefined,":{}}}